FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308403930> ?p ?o ?g. }

• W4308403930 endingPage "160" @default.
• W4308403930 startingPage "149" @default.
• W4308403930 abstract "<b><i>Introduction:</i></b> Biologics are used in the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The purpose of this retrospective study was to evaluate the effects of biologics initiated for asthma on coexistent CRS and the influence of comorbid factors, including aspirin-exacerbated respiratory disease (AERD) and secretory otitis media (SOM). <b><i>Methods:</i></b> A review of electronic health records (2009–2020) at a Finnish tertiary center was conducted to identify CRS patients treated with biologics for their asthma. We identified the type of biologic and treatment response, by comparing nasal polyp score (NPS), sinonasal outcome test (SNOT)-22, need for oral corticosteroids (OCS) and antibiotics, frequency of visits, and endoscopic sinus surgeries (ESS) pretreatment and during treatment. <b><i>Results:</i></b> 55 patients were treated with anti-immunoglobulin E (IgE) (<i>n</i> = 18) or anti-interleukin-5/5-receptor (IL-5/5R) (<i>n</i> = 37) biologics. Treatment lasted for an average of 4.1 years. Seventy-five percent (<i>n</i> = 41) had CRSwNP and 25% (<i>n</i> = 14) had CRSsNP. Of all patients, 24% (<i>n</i> = 13) had comorbid AERD and 22% (<i>n</i> = 12) had SOM. Biologic therapy reduced the need for OCS courses (anti-IgE, <i>n</i> = 17, <i>p</i> = 0.03; anti-IL-5/5R, <i>n</i> = 35, <i>p</i> = 0.01) and for daily OCS in anti-IL-5/5R (<i>n</i> = 35, <i>p</i> = 0.001) but not in anti-IgE patients (<i>n</i> = 16, <i>p</i> = 0.07). Biologics also improved NPS by 0.5 point (<i>n</i> = 32, <i>p</i> = 0.009) and SNOT-22 by 14 points (<i>n</i> = 7, <i>p</i> = 0.02) in CRSwNP patients. The overall discontinuation rate was 37.7% (<i>n</i> = 20) and was independent of type of biologic. <b><i>Conclusion:</i></b> Treatment with anti-IgE and/or anti-IL-5/5R biologics reduced the overall need for OCS medication in individuals with asthma and concomitant CRS, but despite this, the discontinuation rate was high." @default.
• W4308403930 created "2022-11-11" @default.
• W4308403930 creator A5020251479 @default.
• W4308403930 creator A5022412636 @default.
• W4308403930 creator A5030173913 @default.
• W4308403930 creator A5033385154 @default.
• W4308403930 creator A5051519864 @default.
• W4308403930 creator A5052687269 @default.
• W4308403930 creator A5072790450 @default.
• W4308403930 creator A5088096457 @default.
• W4308403930 date "2022-11-07" @default.
• W4308403930 modified "2023-09-27" @default.
• W4308403930 title "Real-Life Experience of Biologic Treatment for Asthma on Chronic Rhinosinusitis: A Finnish Cohort" @default.
• W4308403930 doi "https://doi.org/10.1159/000526365" @default.
• W4308403930 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36349770" @default.
• W4308403930 hasPublicationYear "2022" @default.
• W4308403930 type Work @default.
• W4308403930 citedByCount "0" @default.
• W4308403930 crossrefType "journal-article" @default.
• W4308403930 hasAuthorship W4308403930A5020251479 @default.
• W4308403930 hasAuthorship W4308403930A5022412636 @default.
• W4308403930 hasAuthorship W4308403930A5030173913 @default.
• W4308403930 hasAuthorship W4308403930A5033385154 @default.
• W4308403930 hasAuthorship W4308403930A5051519864 @default.
• W4308403930 hasAuthorship W4308403930A5052687269 @default.
• W4308403930 hasAuthorship W4308403930A5072790450 @default.
• W4308403930 hasAuthorship W4308403930A5088096457 @default.
• W4308403930 hasConcept C126322002 @default.
• W4308403930 hasConcept C141105273 @default.
• W4308403930 hasConcept C159654299 @default.
• W4308403930 hasConcept C203014093 @default.
• W4308403930 hasConcept C2776042228 @default.
• W4308403930 hasConcept C2777768476 @default.
• W4308403930 hasConcept C2781390199 @default.
• W4308403930 hasConcept C71924100 @default.
• W4308403930 hasConcept C72563966 @default.
• W4308403930 hasConcept C90924648 @default.
• W4308403930 hasConceptScore W4308403930C126322002 @default.
• W4308403930 hasConceptScore W4308403930C141105273 @default.
• W4308403930 hasConceptScore W4308403930C159654299 @default.
• W4308403930 hasConceptScore W4308403930C203014093 @default.
• W4308403930 hasConceptScore W4308403930C2776042228 @default.
• W4308403930 hasConceptScore W4308403930C2777768476 @default.
• W4308403930 hasConceptScore W4308403930C2781390199 @default.
• W4308403930 hasConceptScore W4308403930C71924100 @default.
• W4308403930 hasConceptScore W4308403930C72563966 @default.
• W4308403930 hasConceptScore W4308403930C90924648 @default.
• W4308403930 hasIssue "2" @default.
• W4308403930 hasLocation W43084039301 @default.
• W4308403930 hasLocation W43084039302 @default.
• W4308403930 hasOpenAccess W4308403930 @default.
• W4308403930 hasPrimaryLocation W43084039301 @default.
• W4308403930 hasRelatedWork W1983228842 @default.
• W4308403930 hasRelatedWork W2132298298 @default.
• W4308403930 hasRelatedWork W2287496702 @default.
• W4308403930 hasRelatedWork W2348548965 @default.
• W4308403930 hasRelatedWork W2352748590 @default.
• W4308403930 hasRelatedWork W2405551697 @default.
• W4308403930 hasRelatedWork W2413350132 @default.
• W4308403930 hasRelatedWork W2473471207 @default.
• W4308403930 hasRelatedWork W2978492413 @default.
• W4308403930 hasRelatedWork W1590722964 @default.
• W4308403930 hasVolume "184" @default.
• W4308403930 isParatext "false" @default.
• W4308403930 isRetracted "false" @default.
• W4308403930 workType "article" @default.